Enliven reported a net loss of USD 29.7 million for Q4 2025 and a net loss per share of USD 0.48 (basic and diluted). R&D expenses were USD 21.2 million for Q4 2025, while G&A expenses were USD 13.0 million. For FY 2025, Enliven posted a net loss of USD 103.7 million and a net loss per share of USD 1.83 (basic and diluted), with R&D expenses of USD 85.9 million and G&A expenses of USD 33.8 million. Cash, cash equivalents and marketable securities totaled USD 462.6 million as of Dec. 31, 2025, which Enliven said is expected to fund operations into the first half of 2029. On the business side, Enliven highlighted positive initial Phase 1b data from its ongoing ENABLE trial of ELVN-001 in relapsed, refractory or intolerant chronic myeloid leukemia (CML). As of Dec. 22, 2025, 60 patients were enrolled; 53% had received four or more prior TKIs, 67% had received prior asciminib and 32% prior ponatinib. By 24 weeks, cumulative major molecular response (MMR) was 47% in the 80 mg once-daily cohort (n=19) and 69% in the 60/120 mg once-daily cohorts (n=26), with deep molecular response (DMR) of 16% (n=19) and 35% (n=26), respectively. Enliven said it expects a mid-year 2026 presentation of additional Phase 1 data, plans regulatory alignment with the FDA on dose selection and Phase 3 design, and anticipates initiating its Phase 3 ENABLE-2 pivotal trial in the second half of 2026. The company also noted leadership and board changes, including Rick Fair’s appointment as CEO in December 2025 and Scott Garland joining the board in January 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603031605PR_NEWS_USPR_____LA99510) on March 03, 2026, and is solely responsible for the information contained therein.
Comments